The Compounding
Pharmacy
Reckoning.
Why the quiet wave of 503A enforcement letters matters more than the Ozempic shortage ever did — and the three signals that will decide the next ninety days.
- 1 Ozempic shortage: what's actually in the vials
- 2 Tirzepatide trials, read-in-full
- 3 NAD+ clinics: follow the money
- 4 A close read of continuous glucose monitors
The Brief is not open for signups yet. Sign-up goes live when the newsletter launches — no address is collected in the meantime.
No tracking, ever Signups open at launch
Five things in every issue, and nothing else.
- № 01
One story, reported in full
Every issue leads with a deep read on the week's most consequential story. Not a summary of someone else's reporting.
- № 02
Four links that matter
Studies, filings, and interviews — annotated. If we link it, we've read it. If we cite a number, we've checked it.
- № 03
A weekly review
One product, clinic, or protocol, benchmarked against the evidence. Conflicts of interest disclosed at the top.
- № 04
Reader mail
Questions answered by the editorial team — not by an intern with WebMD open. Names used only with permission.
- № 05
Zero tracking pixels
No open tracking. No click tracking. No behavioral ads. Your inbox is yours.
Small print, in large type.
-
The plan is once a week, with the occasional breaking-news bulletin only when a story genuinely can't wait. The Brief hasn't launched yet, so nothing is being sent today.
-
Yes. The Brief will be free to read.
-
Every issue will carry a one-click unsubscribe link at the bottom — no confirmation page, no survey.
-
The Brief is written by the Wellness Wire editorial team. Every piece is fact-checked before it ships.
-
Once signups open, we'll use it to send you The Brief and nothing else — we won't sell, rent, share, or enrich it, and we don't use open- or click-tracking pixels. Email delivery is handled by our email provider.
-
Not yet — The Brief hasn't published its first issue. Once issues start shipping we'll add an archive.
When it launches,
you'll be first.
The Brief is a work in progress. Signups open at launch — check back soon.
No tracking, ever Signups open at launch